Scribe Therapeutics raised new capital in a CRISPR-focused IPO priced at $15 per share, extending what industry watchers describe as a strong run of biotech public debuts. The offering included 8.6 million shares for gross proceeds of about $129 million, with the company starting trading on Nasdaq under ticker SCTX. The IPO is intended to support a pipeline led by a genetic medicine that represses target-gene expression without permanent edits. The listing arrived as markets continued rewarding early-stage platform narratives in gene medicine and cardiometabolic targets.